Solara Active Pharma Sciences enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


2,910	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
25.1	7.5	4.0	8.4	8.7
2.7	2.7	2.7	2.9	2.2
665	665	776	1,000	1,001
3,552	—	—	—	—
639	657	772	991	992
₹798.07	—	—	—	—

2,103	1,920	1,873	1,936	2,504
31.6%	34.6%	41.4%	51.6%	40.0%
0.19×	—	—	—	—

2.31×	—	—	—	—
15.19×	—	—	—	—
27.57×	—	—	—	—
35.49×	—	—	—	—
1,535	1,369	1,284	1,289	1,444
234	187	206	−95.2	134
129	87.1	107	−199	22.7
—	153	213	109	156
100	100	173	67.8	44.9
—	100	173	67.8	0.9
—	52.8	39.9	41.1	111

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health

₹ CrorePeersINDSWFTLAB DCAL SMSPHARMA HIKAL PANACEABIO SAIPARENT INDOCO UNICHEMLABMcap ₹2,910 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	2,910.1
- Cash, Equiv & ST Investments	8.7	8.4	4.0	7.5	25.1
+ Minority Interest	2.2	2.9	2.7	2.7	2.7
+ Total Debt	1,001.2	999.9	776.1	664.5	664.5
Enterprise Value	—	—	—	—	3,552.2
Net Debt (memo)	992.4	991.5	772.1	657.1	639.5
EV per Share	—	—	—	—	798.07

Total Capital	2,503.6	1,936.5	1,873.0	1,920.1	2,103.3
Total Debt/Total Capital	39.99	51.63	41.43	34.61	31.60
Total Debt/EV	—	—	—	—	0.19

EV/Sales	—	—	—	—	2.31
EV/EBITDA	—	—	—	—	15.19
EV/EBIT	—	—	—	—	27.57
EV/Free Cash Flow	—	—	—	—	35.49
Reference Items — Trailing FY Values
Sales	1,443.8	1,288.9	1,283.8	1,369.0	1,535.2
EBITDA	133.9	-95.2	206.3	186.8	233.8
EBIT	22.7	-198.5	107.0	87.1	128.9
Operating Cash Flow	156.3	108.9	212.8	152.9	—
Free Cash Flow	44.9	67.8	172.9	100.1	100.1
FCFF (free cash flow to the firm)	0.9	67.8	172.9	100.1	—
Capital Expenditure	111.3	41.1	39.9	52.8	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.